https://scholars.lib.ntu.edu.tw/handle/123456789/633544
標題: | Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer | 作者: | Dent, Rebecca Oliveira, Mafalda Isakoff, Steven J Im, Seock-Ah Espié, Marc Blau, Sibel Tan, Antoinette R CHIUN-SHENG HUANG et al., |
關鍵字: | First-line therapy; Ipatasertib; Oral; PI3K/AKT; Triple-negative breast cancer | 公開日期: | 九月-2021 | 卷: | 189 | 期: | 2 | 來源出版物: | Breast cancer research and treatment | 摘要: | In LOTUS (NCT02162719), adding the oral AKT inhibitor ipatasertib to first-line paclitaxel for locally advanced/metastatic triple-negative breast cancer (aTNBC) improved progression-free survival (PFS; primary endpoint), with an enhanced effect in patients with PIK3CA/AKT1/PTEN-altered tumors (FoundationOne next-generation sequencing [NGS] assay). We report final overall survival (OS) results. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633544 | ISSN: | 01676806 | DOI: | 10.1007/s10549-021-06143-5 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。